FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:659-660 August 29, 1996 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

An association between appetite-suppressant drugs and primary pulmonary hypertension is reported by Abenhaim et al. in this issue of the Journal.¹ This important finding requires careful assessment, because the prevalence of obesity is increasing and sustained weight reduction has been difficult to achieve without drug treatment. Moreover, the appetite-suppressant drug dexfenfluramine (Redux) has recently become available in the United States. The current receptive climate for pharmacotherapy reflects a paradigm shift: obesity is now recognized as a chronic disease that requires long-term treatment. Obesity results from a complex interaction of genetic, behavioral, and environmental factors. Because exercise, diet, and behavioral . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Day, A. (2002). Lessons from the Women's Health Initiative: primary prevention and gender health. CMAJ 167: 361-362 [Full Text]  
• Hauptman, J., Lucas, C., Boldrin, M. N., Collins, H., Segal, K. R. (2000). Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Arch Fam Med 9: 160-167 [Abstract] [Full Text]  
• Bray, G. A., Greenway, F. L. (1999). Current and Potential Drugs for Treatment of Obesity. Endocr. Rev. 20: 805-875 [Abstract] [Full Text]  
• Allison, D. B., Fontaine, K. R., Manson, J. E., Stevens, J., VanItallie, T. B. (1999). Annual Deaths Attributable to Obesity in the United States. JAMA 282: 1530-1538 [Abstract] [Full Text]  
• Psaty, B. M., Weiss, N. S., Furberg, C. D., Koepsell, T. D., Siscovick, D. S., Rosendaal, F. R., Smith, N. L., Heckbert, S. R., Kaplan, R. C., Lin, D., Fleming, T. R., Wagner, E. H. (1999). Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease. JAMA 282: 786-790 [Full Text]  
• Fishman, A. P. (1999). Aminorex to Fen/Phen : An Epidemic Foretold. Circulation 99: 156-161 [Full Text]  
• (1997). Weight Loss Medications: More Lost Than Gained. JWatch Psychiatry 1997: 18-18 [Full Text]  
• Rosenbaum, M., Leibel, R. L., Hirsch, J. (1997). Obesity. NEJM 337: 396-407 [Full Text]  
• Salzman, R., Stone, L. R., Douglas, E. F., Blank, N. K., Erisman, M. D., Angell, M., Kassirer, J. P. (1997). Editorials and Conflicts of Interest. NEJM 336: 728-729 [Full Text]  
• Sobieraj, J., Schembre, D. B., Boynton, K. K., Fishman, A. P., Hoffman, R. M., Upson, D., Dhurandhar, N. V., Atkinson, R. L., Williamson, D. F., Abenhaim, L., Rich, S., Benichou, J., Begaud, B., The International Primary Pulmonary Hypertension S, (1997). Appetite-Suppressant Drugs and Primary Pulmonary Hypertension. NEJM 336: 510-513 [Full Text]  
• Angell, M., Kassirer, J. P. (1996). Editorials and Conflicts of Interest. NEJM 335: 1055-1056 [Full Text]  
• Manson, J. E., Faich, G. A. (1996). Conflicts of Interest -- Editorialists Respond. NEJM 335: 1064-1065 [Full Text]